Pathalys Pharma

Executive Summary

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company headquartered in Durham, North Carolina, dedicated to developing novel small-molecule therapies for chronic kidney disease (CKD). Founded in 2020 with backing from Catalys Pacific and DaVita Venture Group, the company's initial focus is on improving the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease. SHPT is a common and serious complication of CKD that leads to bone disease and cardiovascular risk, and current therapies have limitations. Pathalys is advancing a pipeline of enhanced therapeutics aimed at addressing the high unmet need in this patient population. The company's lead candidate is in Phase 3 clinical development, representing a significant derisking step given the advanced stage. As a private entity, Pathalys has not disclosed its valuation or total funding, but its strategic partnerships and late-stage focus position it as a potential acquisition target or IPO candidate in the nephrology space. The company's success hinges on positive Phase 3 data and regulatory clarity, which could redefine SHPT management.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout60% success
• Q1 2027Pre-NDA Meeting with FDA75% success
• Q2 2026Series C Financing or Partnership Announcement50% success